NASDAQ:MIRM Mirum Pharmaceuticals (MIRM) Stock Forecast, Price & News $30.72 -1.20 (-3.76%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$30.69▼$32.1250-Day Range$24.63▼$32.8552-Week Range$17.32▼$33.39Volume296,142 shsAverage Volume713,889 shsMarket Capitalization$1.18 billionP/E RatioN/ADividend YieldN/APrice Target$53.33 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Mirum Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.20 Rating ScoreUpside/Downside73.6% Upside$53.33 Price TargetShort InterestBearish20.15% of Float Sold ShortDividend StrengthN/ASustainability-1.69Upright™ Environmental ScoreNews Sentiment0.33Based on 4 Articles This WeekInsider TradingAcquiring Shares$4.32 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($2.41) to $1.03 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.30 out of 5 starsMedical Sector296th out of 965 stocksPharmaceutical Preparations Industry123rd out of 456 stocks 3.6 Analyst's Opinion Consensus RatingMirum Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $53.33, Mirum Pharmaceuticals has a forecasted upside of 73.6% from its current price of $30.72.Amount of Analyst CoverageMirum Pharmaceuticals has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted20.15% of the float of Mirum Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverMirum Pharmaceuticals has a short interest ratio ("days to cover") of 9.Change versus previous monthShort interest in Mirum Pharmaceuticals has recently increased by 0.59%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldMirum Pharmaceuticals does not currently pay a dividend.Dividend GrowthMirum Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMirum Pharmaceuticals has received a 61.01% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Liver-disease medication (A05)", "Clinical research services for physiological diseases ", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Mirum Pharmaceuticals is -1.69. Previous Next 2.4 News and Social Media Coverage News SentimentMirum Pharmaceuticals has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Mirum Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 8 people have searched for MIRM on MarketBeat in the last 30 days. This is a decrease of -27% compared to the previous 30 days.MarketBeat Follows4 people have added Mirum Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Mirum Pharmaceuticals insiders have bought 459.69% more of their company's stock than they have sold. Specifically, they have bought $4,323,280.00 in company stock and sold $772,439.00 in company stock.Percentage Held by Insiders24.06% of the stock of Mirum Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Mirum Pharmaceuticals are expected to grow in the coming year, from ($2.41) to $1.03 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mirum Pharmaceuticals is -6.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mirum Pharmaceuticals is -6.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMirum Pharmaceuticals has a P/B Ratio of 7.98. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Mirum Pharmaceuticals (NASDAQ:MIRM) StockMirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of primary sclerosing cholangitis and primary biliary cholangitis in adults. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.Read More MIRM Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MIRM Stock News HeadlinesSeptember 24, 2023 | msn.comMirum Pharmaceuticals: An Attractive Stock To Watch For Its Liver Disease FranchiseSeptember 21, 2023 | finance.yahoo.comMirum Pharmaceuticals to Present at the 2023 Cantor Global Healthcare ConferenceSeptember 24, 2023 | Legacy Research (Ad)WARNING: Mandatory U.S. Dollar Recall is Weeks AwayIf you have any U.S. dollars in your bank account… You must see this shocking video exposing the government’s new plan to recall the U.S. dollar. According to Business Insider, this recall “could be imminent.” And if you don’t prepare now, you could end up holding a bunch of worthless U.S. dollars.September 21, 2023 | americanbankingnews.comMirum Pharmaceuticals (NASDAQ:MIRM) Receives New Coverage from Analysts at JMP SecuritiesSeptember 15, 2023 | finance.yahoo.comDirector Michael Grey Sells 14,608 Shares of Mirum Pharmaceuticals Inc (MIRM)September 15, 2023 | finance.yahoo.comStrength Seen in Mirum Pharmaceuticals, Inc. (MIRM): Can Its 8.0% Jump Turn into More Strength?September 15, 2023 | finance.yahoo.comMirum Pharmaceuticals Merits a Healthy Endorsement Based on Its ChartsSeptember 15, 2023 | americanbankingnews.comMirum Pharmaceuticals' (MIRM) Buy Rating Reaffirmed at HC WainwrightSeptember 24, 2023 | Chaikin Analytics (Ad)This Stock Could Go Up 66% or More.Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023. Click here to get his latest buy. More here.September 15, 2023 | americanbankingnews.comMirum Pharmaceuticals (NASDAQ:MIRM) Sees Large Volume Increase After Insider Buying ActivitySeptember 14, 2023 | finance.yahoo.comDirector Patrick Heron Buys 8,437 Shares of Mirum Pharmaceuticals IncSeptember 14, 2023 | americanbankingnews.comEric Bjerkholt Purchases 10,000 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) StockSeptember 13, 2023 | finance.yahoo.comInsider Buying: CFO Eric Bjerkholt Acquires 10,000 Shares of Mirum Pharmaceuticals IncSeptember 13, 2023 | markets.businessinsider.comAnalyst Ratings for Mirum PharmaceuticalsSeptember 11, 2023 | msn.comMirum Pharmaceuticals appointed Eric Bjerkholt as CFOSeptember 11, 2023 | finance.yahoo.comMirum Pharmaceuticals Announces the Appointment of Eric Bjerkholt as Chief Financial OfficerSeptember 6, 2023 | finance.yahoo.comMirum Pharma (MIRM) Stock Rises 42% Year to Date: Here's WhyAugust 8, 2023 | markets.businessinsider.comRobert W. Baird Reaffirms Their Buy Rating on Mirum Pharmaceuticals (MIRM)August 4, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (MIRM) and Axsome Therapeutics (AXSM)August 4, 2023 | seekingalpha.comMirum Pharmaceuticals, Inc. 2023 Q2 - Results - Earnings Call PresentationAugust 3, 2023 | finance.yahoo.comMirum Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business UpdateJuly 28, 2023 | finance.yahoo.comMirum Pharmaceuticals to Announce Second Quarter 2023 Financial Results and Host Conference Call on August 3, 2023July 25, 2023 | finance.yahoo.comMirum’s LIVMARLI® Now Authorized in Canada for Cholestatic Pruritus in Patients with Alagille SyndromeJuly 20, 2023 | finance.yahoo.comWith 67% institutional ownership, Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) is a favorite amongst the big gunsJuly 18, 2023 | markets.businessinsider.comRaymond James Maintains Strong Buy Rating for Mirum Pharmaceuticals: Here's What You Need To KnowJuly 18, 2023 | msn.comHC Wainwright & Co. Maintains Mirum Pharmaceuticals (MIRM) Buy RecommendationJuly 17, 2023 | markets.businessinsider.comTravere Therapeutics Offloads Bile Acid Product Portfolio: Says Divestment Strengthens Financial FoundationSee More Headlines Receive MIRM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mirum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address MIRM Company Calendar Last Earnings8/03/2023Today9/24/2023Next Earnings (Estimated)11/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MIRM CUSIPN/A CIK1759425 Webmirumpharma.com Phone(650) 667-4085FaxN/AEmployees213Year FoundedN/APrice Target and Rating Average Stock Price Forecast$53.33 High Stock Price Forecast$84.00 Low Stock Price Forecast$30.00 Forecasted Upside/Downside+73.6%Consensus RatingBuy Rating Score (0-4)3.20 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($4.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-135,660,000.00 Net Margins-152.27% Pretax Margin-151.70% Return on Equity-103.59% Return on Assets-36.81% Debt Debt-to-Equity Ratio3.89 Current Ratio6.59 Quick Ratio6.44 Sales & Book Value Annual Sales$77.06 million Price / Sales15.27 Cash FlowN/A Price / Cash FlowN/A Book Value$3.85 per share Price / Book7.98Miscellaneous Outstanding Shares38,300,000Free Float29,084,000Market Cap$1.18 billion OptionableNot Optionable Beta1.25 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Christopher Peetz (Age 44)Pres, CEO & Director Comp: $1.09MMr. Peter Radovich M.B.A. (Age 45)Ph.D., Chief Operating Officer Comp: $732.15kDr. Pamela Vig Ph.D. (Age 52)Head of R&D Comp: $678.2kMs. Lara Longpre MBA (Age 53)MSC, Chief Devel. Officer Comp: $678.2kJolanda HoweSr. VP & Global ControllerAndrew McKibbenVP of Investor Relations and Fin.Mr. Paul K. RossChief Compliance OfficerMs. Erin Campany (Age 55)Sr. VP of HR Dr. Ian Clements Ph.D. (Age 54)Consultant Ms. Vinita P. KumarSr. vice Pres of QualityMore ExecutivesKey CompetitorsSyndax PharmaceuticalsNASDAQ:SNDXDisc Medicine OpcoNASDAQ:IRONRevance TherapeuticsNASDAQ:RVNCDay One BiopharmaceuticalsNASDAQ:DAWNSage TherapeuticsNASDAQ:SAGEView All CompetitorsInsiders & InstitutionsBarclays PLCSold 12,313 shares on 9/21/2023Ownership: 0.750%Michael G. GreySold 14,216 sharesTotal: $454,912.00 ($32.00/share)Patrick J HeronBought 4,687 shares on 9/11/2023Total: $142,016.10 ($30.30/share)Eric BjerkholtBought 10,000 shares on 9/11/2023Total: $296,500.00 ($29.65/share)Patrick J HeronBought 147,991 shares on 8/31/2023Total: $3.88 M ($26.25/share)View All Insider TransactionsView All Institutional Transactions MIRM Stock - Frequently Asked Questions Should I buy or sell Mirum Pharmaceuticals stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Mirum Pharmaceuticals in the last twelve months. There are currently 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MIRM shares. View MIRM analyst ratings or view top-rated stocks. What is Mirum Pharmaceuticals' stock price forecast for 2023? 5 brokerages have issued 1-year price targets for Mirum Pharmaceuticals' stock. Their MIRM share price forecasts range from $30.00 to $84.00. On average, they expect the company's stock price to reach $53.33 in the next twelve months. This suggests a possible upside of 73.6% from the stock's current price. View analysts price targets for MIRM or view top-rated stocks among Wall Street analysts. How have MIRM shares performed in 2023? Mirum Pharmaceuticals' stock was trading at $19.50 on January 1st, 2023. Since then, MIRM stock has increased by 57.5% and is now trading at $30.72. View the best growth stocks for 2023 here. When is Mirum Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023. View our MIRM earnings forecast. How were Mirum Pharmaceuticals' earnings last quarter? Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) issued its quarterly earnings data on Thursday, August, 3rd. The company reported ($0.92) EPS for the quarter, missing analysts' consensus estimates of ($0.81) by $0.11. The business had revenue of $37.50 million for the quarter, compared to analyst estimates of $30 million. Mirum Pharmaceuticals had a negative trailing twelve-month return on equity of 103.59% and a negative net margin of 152.27%. What ETFs hold Mirum Pharmaceuticals' stock? ETFs with the largest weight of Mirum Pharmaceuticals (NASDAQ:MIRM) stock in their portfolio include Simplify Propel Opportunities ETF (SURI).Virtus LifeSci Biotech Products ETF (BBP). What other stocks do shareholders of Mirum Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Mirum Pharmaceuticals investors own include Pfizer (PFE), Fulcrum Therapeutics (FULC), OPKO Health (OPK), Vaxart (VXRT), Advanced Micro Devices (AMD), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), Trevena (TRVN), VBI Vaccines (VBIV) and Dynavax Technologies (DVAX). When did Mirum Pharmaceuticals IPO? (MIRM) raised $75 million in an initial public offering (IPO) on Thursday, July 18th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Evercore ISI and Guggenheim Securities acted as the underwriters for the IPO and Raymond James and Roth Capital Partners were co-managers. What is Mirum Pharmaceuticals' stock symbol? Mirum Pharmaceuticals trades on the NASDAQ under the ticker symbol "MIRM." Who are Mirum Pharmaceuticals' major shareholders? Mirum Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Eventide Asset Management LLC (9.03%), BlackRock Inc. (5.30%), Rock Springs Capital Management LP (4.75%), State Street Corp (3.90%), Cadian Capital Management LP (3.30%) and Polar Capital Holdings Plc (2.42%). Insiders that own company stock include Christopher Peetz, Eric Bjerkholt, Ian Clements, James E Flynn, John A Maurer, Jolanda Howe, Lara Longpre, Michael G Grey, Niall O'donnell, Pamela Vig, Patrick J Heron and Peter Radovich. View institutional ownership trends. How do I buy shares of Mirum Pharmaceuticals? Shares of MIRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Mirum Pharmaceuticals' stock price today? One share of MIRM stock can currently be purchased for approximately $30.72. How much money does Mirum Pharmaceuticals make? Mirum Pharmaceuticals (NASDAQ:MIRM) has a market capitalization of $1.18 billion and generates $77.06 million in revenue each year. The company earns $-135,660,000.00 in net income (profit) each year or ($4.75) on an earnings per share basis. How many employees does Mirum Pharmaceuticals have? The company employs 213 workers across the globe. How can I contact Mirum Pharmaceuticals? Mirum Pharmaceuticals' mailing address is 950 TOWER LANE SUITE 1050, FOSTER CITY CA, 94404. The official website for the company is mirumpharma.com. The company can be reached via phone at (650) 667-4085 or via email at ir@mirumpharma.com. This page (NASDAQ:MIRM) was last updated on 9/24/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mirum Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.